Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 8/20 | 0.44 |
| ▸ | IL6ST | P40189 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46356 | 1.00 | NAAA (0.48) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL2501454 | 1.00 | NAAA (0.48) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL5558781 | 0.95 | NAAA (0.44) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL7346804 | 0.92 | HDAC1 (0.46) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL6422192 | 0.92 | HDAC1 (0.46) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL5564250 | 0.91 | NAAA (0.42) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL7306476 | 0.88 | NAAA (0.47) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL13926346 | 0.87 | NAAA (0.44) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL291952 | 0.86 | NAAA (0.49) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL237075 | 0.86 | NAAA (0.49) | NAAAABCB1FAAHIDH1IL6ST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| EP-4735423-A1 | KV7 MODULATORS | Saniona A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-07-08 | — | — | US | disclosed |
| US-20250066351-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2025003343-A1 | KV7 MODULATORS | SANIONA A/S (DK) | 2025-01-02 | — | — | WO | disclosed |
| EP-4460501-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2024-09-12 | — | — | US | disclosed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3572405-B9 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| US-20080255136-A1 | PYRROLIDONES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2008-10-16 | — | — | US | disclosed |
| EP-1841425-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC A Delware Limited Liability Company (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081554-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
| US-20040157859-A1 | Pyrrolidones with anti-HIV activity | IRM LLC, A DELAWARE LLC (BM) | 2004-08-12 | — | — | US | disclosed |
| WO-2004037784-A2 | PYRROLIDONES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2004-05-06 | — | — | WO | disclosed |
| US-6133275-A | ALPHA 1 ADRENORECEPTOR ANTAGONISTS; TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER UROLOGICAL DISEASES E.G., BLADDER OUTLET OBSTRUCTION), NEUROGENIC BLADDER AND GYNECOLOGICAL SYNDROMES, E.G., DYSMENORRHEA; UTERINE MUSCLE RELAXANTS | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1999057122-A1 | 3-PHENYLPYRROLE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255136-A1 | PYRROLIDONES WITH ANTI-HIV ACTIVITY | PREP, DHPS, PDCD11 | NAAA 2589/4885ABCB1 2389/4885FAAH 3212/4885 |
| US-20040157859-A1 | Pyrrolidones with anti-HIV activity | PREP, DHPS, PDCD11 | NAAA 2589/4885ABCB1 2389/4885FAAH 3212/4885 |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNK2 | NAAA 2102/4885ABCB1 2043/4885FAAH 3659/4885 |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | NAAA 1634/4885ABCB1 844/4885FAAH 2779/4885 |
| US-20250066351-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNA1 | NAAA 2128/4885ABCB1 1450/4885FAAH 2691/4885 |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | MALT1, FKBP5, PREP | NAAA 2882/4885ABCB1 804/4885FAAH 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.